Gritstone bio Announces Private Placement of $45.0 Million
25 oct. 2022 07h01 HE
|
Gritstone bio
EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases
25 oct. 2022 07h00 HE
|
Gritstone bio
-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination -- -- Interim results from...
Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases
19 oct. 2022 07h00 HE
|
Gritstone bio
-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates against SARS-CoV-2 -- EMERYVILLE, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Gritstone...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 oct. 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 sept. 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022
12 sept. 2022 07h00 HE
|
Gritstone bio
-- SLATE vaccines (version 1 and SLATE-KRAS) demonstrate early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer...
Gritstone to Participate in Two Upcoming Investor Conferences
01 sept. 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 août 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
15 août 2022 16h05 HE
|
Gritstone bio
-- Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells, including cytotoxic CD8+ T cells -- -- T cells linked to...
Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors
10 août 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...